Usefulness of serum p53 antibody measurement in colorectal cancer: An examination of 1384 primary colorectal cancer patients

Surgery Today

Volumn 44, Issue 8, 2014, Pages 1529-1535

  Yamaguchi, Tetsuji ^a   Takii, Yasumasa ^a   Maruyama, Satoshi ^a  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

Colorectal cancer; Detecting method; Prognostic indicator; Serum p53 antibody; Tumor marker

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; P53 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; COLORECTAL CARCINOMA; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; ADOLESCENT; BLOOD; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84904402773     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0703-5     Document Type: Article

References (16)

1. Angelopoulou K, Stratis M, Diamandis EP. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Can. 1997;70:46-51. (Pubitemid 27059704)
2. Shimada H, Nakajima K, Ochiai T, Koide Y, Okazumi SI, Matsubara H, et al. Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers. Oncol Rep. 1998;5:871-4. (Pubitemid 28270684)
3. Wurl P, Weigmann F, Meye A, Fittkau M, Rose U, Berger D, et al. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand J Gastroenterol. 1997;32:1147-51. (Pubitemid 27523848)
4. Shimada H, Ochiai T, Nomura F, Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 antibody research group. Cancer. 2003;97:682-9. (Pubitemid 36125846)
5. Ochiai H, Ohishi T, Osumi K, Tokuyama J, Urakami H, Seki S, et al. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today. 2012;42:164-8.
6. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009.
7. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Can. 1994;58:480-7. (Pubitemid 24268085)
8. Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Can. 2001;94:859-63. (Pubitemid 33032835)
9. Lechpammer M, Lukac J, Lechpammer S, Kovacević D, Loda M, Kusić Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis. 2004;19:114-20. (Pubitemid 38239830)
10. Kressner U, Inganas M, Byding S, Blikstad I, Påhlman L, Glimelius B, Lindmark G. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol. 1999;17:593-9. (Pubitemid 29075247)
11. Peyrat JP, Bonnetterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for loco-regional breast cancer. Lancet. 1995;345:621-2.
12. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer. 1996;78:2146-52.
13. Shiota G, Kishimoto Y, Suyama A, et al. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol. 1997;27:661-8. (Pubitemid 27448750)
14. Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okubo M, et al. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci. 2000;45:122-8. (Pubitemid 30111698)
15. Houbiers JG, van der Burg SH, van de Watering LMG, Okubo M, Katayama S, Harada K, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Can. 1995;72:637-41.
16. Suppiah A, Alabi A, Madden L, Hartley JE, Monson JR, Greenman J. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int J Colorectal Dis. 2008;23:595-600.